Bernhard Resch1, Ina Michel-Behnke. 1. aResearch Unit for Neonatal Infectious Diseases and Epidemiology, Department of Pediatrics, Medical University of Graz, Graz, Austria. bernhard.resch@medunigraz.at
Abstract
PURPOSE OF REVIEW: Lower respiratory tract infections multiply morbidity and mortality within patients with significant congenital heart disease (CHD). For respiratory syncytial virus (RSV), one of the most important pathogens, immunoprophylaxis with palivizumab has successfully been introduced. The question is which patients will benefit most from this costly preventive treatment. RECENT FINDINGS: The era after the introduction of palivizumab has revealed a steep decrease in mortality. The markers of success - hospital stays, admission to the intensive care unit, days on mechanical ventilation, and death - consistently favor immunoprophylaxis. The key point of treatment success remains in all cases a careful patient selection, adherence to a time limit of 30 days between the injections and early use after cardiac surgery with cardiopulmonary bypass, as well as avoidance of nosocomial-acquired infections. Preventive therapy with palivizumab in patients with CHD has been investigated in terms of operating efficiency - with the lowest costs per quality-adjusted life years compared with preterm infants with or without bronchopulmonary dysplasia. SUMMARY: The burden of RSV disease will decline, once a vaccine is available. Meanwhile, immunoprophylaxis with palivizumab is a useful tool for high-risk patients to reduce comorbidity and fatal outcome. Pharmacoeconomic considerations measuring quality-adjusted life years indicate important information about cost-effectiveness.
PURPOSE OF REVIEW: Lower respiratory tract infections multiply morbidity and mortality within patients with significant congenital heart disease (CHD). For respiratory syncytial virus (RSV), one of the most important pathogens, immunoprophylaxis with palivizumab has successfully been introduced. The question is which patients will benefit most from this costly preventive treatment. RECENT FINDINGS: The era after the introduction of palivizumab has revealed a steep decrease in mortality. The markers of success - hospital stays, admission to the intensive care unit, days on mechanical ventilation, and death - consistently favor immunoprophylaxis. The key point of treatment success remains in all cases a careful patient selection, adherence to a time limit of 30 days between the injections and early use after cardiac surgery with cardiopulmonary bypass, as well as avoidance of nosocomial-acquired infections. Preventive therapy with palivizumab in patients with CHD has been investigated in terms of operating efficiency - with the lowest costs per quality-adjusted life years compared with preterm infants with or without bronchopulmonary dysplasia. SUMMARY: The burden of RSV disease will decline, once a vaccine is available. Meanwhile, immunoprophylaxis with palivizumab is a useful tool for high-risk patients to reduce comorbidity and fatal outcome. Pharmacoeconomic considerations measuring quality-adjusted life years indicate important information about cost-effectiveness.
Authors: Mohammed Omar Alfakhri; Meshal Fahad Alhajji; Abdulrahman Mohammed Alyani; Yahya Zohair Murad; Abdulrahman Eissa Alghannam; Alwaleed Hamad Alqahtani Journal: J Family Med Prim Care Date: 2020-04-30
Authors: Ah Young Kim; Se Yong Jung; Jae Young Choi; Gi Beom Kim; Young-Hwue Kim; Woo Sup Shim; I-Seok Kang; Jo Won Jung Journal: Korean Circ J Date: 2016-09-28 Impact factor: 3.243
Authors: Paul A Checchia; Bosco Paes; Louis Bont; Paolo Manzoni; Eric A F Simões; Brigitte Fauroux; Josep Figueras-Aloy; Xavier Carbonell-Estrany Journal: Infect Dis Ther Date: 2017-01-09
Authors: B Resch; S Kurath-Koller; J Hahn; W Raith; M Köstenberger; A Gamillscheg Journal: Eur J Clin Microbiol Infect Dis Date: 2016-04-28 Impact factor: 3.267